5.5 kD TNF degradation product

Details 5.5 kD TNF degradation product 5.5 kD TNF degradation product

1994-06-13

1996-08-06

Draper, Garnette D.

Drug, bio-affecting and body treating compositions

Lymphokine

424520, 530300, 530350, 530351, 530402, 530407, A61K 3819, C07K 200, C07K 1400

Patent

active

055431399

ABSTRACT:
A particular TNF degradation product is effective as a cytotoxin with respect both to TNF-sensitive and TNF-resistant tumor cells. Pharmaceutical compositions containing this degradation product are thus useful in treating tumors which are otherwise resistant to TNF. In addition, TNF resistance can be measured as a function of the expression of EGF receptors in tumor cells.

REFERENCES:
Wantanabe et al., Immunpharm. Immunotox. (1988) 10(1):109-116.
Aggarwal et al., J. Biol. Chem. (1986) 261(29):13652-13656.
Liddil et al., Cancer Res. (1989) 49:2722-2728.
Ohsawa et al., J. Biochem. (1988) 103:730-734.
Fruehauf et al., J. Immunotherapy(1991) 10:165-173.
Freuhauf et al., J. Natl. Cancer Inst. (1990) 82(14):1206-1209.
Sugarman et al., Cancer Res. (1987) 47:780-786.
Lichtenstein et al., Cancer Res. (1990) 50:7364-7370.
Hudziak et al., Mol. Cell. Biol. (1989) 9(3):1165-1172.
Smith et al., 1987. J. Biol. Chem (262) 15: 6951-6954.
Kunitani et al., 1988 J. Chromatog. 443: 205-220.

Affiliated with

Also associated with

Rating

5.5 kD TNF degradation product does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5.5 kD TNF degradation product, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5.5 kD TNF degradation product will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2189374